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Abstract
Background: The tuberculin skin test (TST) has limitations for latent tuberculosis infection (LTBI) diagnosis in
low-prevalence settings. Previously, all TST-positive individuals referred from the community to Baltimore City
Health Department (BCHD) were offered LTBI treatment, after active TB was excluded. In 2010, BCHD introduced
adjunctive QuantiFERON-TB Gold In-Tube (QFT-GIT) testing for TST-positive referrals. We evaluated costs and
cost-effectiveness of this new diagnostic algorithm.
Methods: A decision-analysis model compared the strategy of treating all TST-positive referrals versus only those
with positive results on adjunctive QFT-GIT testing. Costs were collected at BCHD, and Incremental
Cost-Effectiveness Ratios (ICERs) were utilized to report on cost-effectiveness.
Results: QFT-GIT testing at BCHD cost $43.51 per test. Implementation of QFT-GIT testing was associated with an
ICER of $1,202 per quality-adjusted life-year gained and was considered highly cost-effective. In sensitivity analysis,
the QFT-GIT strategy became cost-saving if QFT-GIT sensitivity increased above 92% or if less than 3.5% of
individuals with LTBI progress to active TB disease.
Conclusions: LTBI screening with TST in low-prevalence settings may lead to overtreatment and increased
expenditures. In this public health clinic, additional QFT-GIT testing of individuals referred for a positive TST was
cost-effective.
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Background
Identifying and treating individuals with latent tubercu-
losis infection (LTBI) prevents progression to active TB
disease and is a key component of tuberculosis (TB)
control strategies in the United States (US) [1-3]. The
US Centers for Disease Control and Prevention (CDC)
currently recommends testing of only individuals at high
risk for M. tuberculosis (MTB) infection or progression
to active TB disease [3]. In the US, LTBI screening
occurs through a mixture of public and private health
sector efforts. In Baltimore City, initial screening for
MTB infection is typically conducted by community pro-
viders, almost exclusively using the tuberculin skin test
(TST) [4]. Baltimore City residents identified with a
positive TST by community sources subsequently may
be referred to the Baltimore City Health Department
(BCHD), where they are provided, free of charge, with
LTBI care. This care includes an assessment of active TB
disease by symptom screening and chest x-ray, and LTBI
treatment using CDC-recommended regimens once
active TB disease is excluded. Prior to 2010, BCHD
conducted no further LTBI testing for these referrals.
However, health department reliance on TST results
from heterogeneous community sources has limitations
[4]. Bacille Calmette-Guerin (BCG) vaccination in
foreign-born individuals or exposure to non-tuberculous
mycobacteria (NTM) may compromise TST specificity.
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Additionally, inter-reader variability of TST results may
lead to misclassifications and false-positive results, par-
ticularly in low-prevalence populations [5]. These limita-
tions may lower the positive predictive value of TST for
identifying individuals at risk for progression to active
TB disease [6].
Interferon-gamma release assays (IGRAs) are emer-
ging tools for the detection of infection with M. tubercu-
losis with some advantages compared to TST, but are
more costly. IGRAs, such as the QuantiFERON-TB Gold
In-Tube (QFT-GIT, Cellestis, Ltd, Carnegie, Australia)
test, are blood tests that measure in vitro interferon-
gamma release from lymphocytes stimulated by antigens
that are specific to M. tuberculosis, resulting in increased
specificity and less cross-reactivity with NTM species or
BCG-vaccination than TST [7-9]. QFT-GIT sensitivity is
comparable to TST, and some studies suggest QFT-GIT
may have a negative predictive value above 99% for iden-
tifying individuals at risk for progression to active TB
disease [6,8,10]. The CDC has recommended that IGRAs
may be used as an alternative to TST for LTBI testing in
most circumstances, and may be preferred for indivi-
duals with a history of BCG-vaccination [9].
LTBI treatment can be resource-intensive for public
health programs. In early 2010, BCHD implemented
additional QFT-GIT testing as part of evaluations for
individuals referred from community providers with sus-
pected LTBI on the basis of a positive TST [4]. Subse-
quently, rates of LTBI diagnosis and treatment were
substantially reduced with high rates of discordance be-
tween BCHD-directed QFT-GIT testing and TST results
from the referral source; only 57% of foreign-born and
36% of US-born individuals referred for a positive TST
had a positive QFT-GIT [4]. These findings are similar
to those reported by others in low-prevalence settings.
In a public health TB clinic in Alberta, Canada, QFT-GIT
was used as a confirmatory test for patients with a positive
TST and only 40% of patients were QFT-GIT positive [11].
Interpretation of discordance is challenging, but may
represent low positive predictive value of TST for identify-
ing LTBI in non-endemic settings due to suboptimal test
specificity [11].
Adjunctive QFT-GIT testing of individuals referred to
public health TB clinics for suspected LTBI on the basis
of a positive TST will incur more diagnostic costs, but
might reduce treatment of individuals with false-positive
TSTs with consequent cost-savings; alternatively, it may
also lead to missed LTBI diagnoses. This study sought to
determine the costs associated with QFT-GIT imple-
mentation at BCHD, and to determine if adjunctive
QFT-GIT testing was a cost-effective LTBI-care strategy
for individuals referred on the basis of a positive TST,
compared to a strategy of considering all TST-positive
referrals to have true LTBI warranting treatment.
Methods
This economic evaluation was conducted from a health-
system perspective, with a target population consisting
of individuals referred to public health clinics with
suspected LTBI on the basis of a positive TST. Target
audiences include city and state health departments, TB
control programs, and public-sector healthcare payers.
Individuals with close-contact to people with active TB
disease were not considered as part of this analysis, since
these represent a patient population with different LTBI
risks. For the cost-effectiveness analyses, a one-year
time-frame was used and the analytic horizon was
extended to the life-expectancy of individuals with sus-
pected LTBI; future costs and QALY’s were discounted
at 3%. We additionally presented budgetary analysis
using a 5 year time-horizon with and without discounting
of future costs from the Public Health Department perspec-
tive. We conducted the analysis using TreeAge Software.
This study did not involve human subjects; protocol was
approved by ethics committees at the Johns Hopkins
University School of Medicine (Baltimore, USA) and the
Baltimore City Health Department.
Study model
We compared two LTBI care strategies at BCHD for
TST-positive referrals using a decision-analysis model
(Figure 1):
1) Standard Algorithm (Standard): TST-positive
individuals are referred to BCHD, which relies on
referral-source TST results with no further LTBI
diagnostic testing. All individuals are evaluated for
active TB disease by symptom screen and chest x-ray,
as well as additional testing as indicated. All individuals
receive baseline liver chemistries. If active TB disease is
excluded and there are no contraindications to LTBI
treatment, then LTBI treatment is provided free-of-charge.
2) QFT-GIT Intervention Algorithm (Intervention):
TST-positive individuals are referred to BCHD, which
subsequently conducts additional QFT-GIT testing on
all referred individuals to assess LTBI status. All
individuals are also evaluated for active TB disease by
symptom screen and chest x-ray, as well as additional
testing as indicated. All individuals receive baseline
liver chemistries. QFT-GIT positive individuals, in
whom active TB disease has been excluded and have no
contraindications to LTBI treatment are provided LTBI
treatment free-of-charge. Individuals with a negative
QFT-GIT are not treated for LTBI.
Key model parameters
Table 1 shows base-case values with ranges and sources
for all key costs and model parameters.
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Epidemiologic, diagnostic, and treatment parameters
The incidence of active TB disease in Baltimore City in
2010 was 5.2/100,000 (population 620,961) [24]. Base-
case analysis parameters were based on data from
BCHD, which annually evaluates approximately 500
individuals, 64% foreign-born, referred by community
providers for a positive TST [4]. Per routine care, all
individuals referred for suspected LTBI are interviewed
by clinical staff for demographics, medical history, and
signs and symptoms of active TB disease, and also re-
ceive a chest x-ray and liver function tests. Patients with
signs or symptoms of active TB disease are evaluated by
sputum smear microscopy, culture, and other testing.
For the base-case analysis, 100% uptake of QFT-GIT
testing and implementation was assumed with 3% of
tests requiring repeat due to processing failure or an in-
determinate result [4]. Without a true reference standard
LTBI diagnostic test, it is impossible to ascertain the true
proportion of LTBI among individuals referred to the
BCHD with a positive TST; we assumed only patients
with LTBI are at risk for progression to active TB
disease. Among individuals referred to BCHD with a
positive TST, only 58% of those who were foreign-born
and 36% of those who were US-born had a positive
QFT-GIT [4]. It is unknown if this test discordance
represents false-positive TST results or false-negative
QFT-GIT results, or some combination. Given these
observed rates of QFT-GIT positivity, true LTBI preva-
lence among referrals was calculated based on estimated
QFT-GIT sensitivity and specificity: true LTBI Preva-
lence = (% test positive + specificity −1)/(sensitivity +
specificity −1). For the base-case, QFT-GIT sensitivity of
81% and specificity of 99% were assumed based on pub-
lished literature [8,9,14]. Reported QFT-GIT sensitivity
for LTBI may be underestimated since test performance
has largely been assessed in people with active TB dis-
ease as a surrogate for LTBI. Longitudinal studies have
shown that less than 1% of individuals with a negative
QFT-GIT progress to active TB disease even in high-risk
groups, suggesting higher QFT-GIT sensitivity for
Figure 1 Schematic of Decision Analysis Model for Cost-Effectiveness Evaluation. Simplified schematic of decision-analysis model. Target
population consists of TST-positive referrals to BCHD. LTBI prevalence among this population was estimated based on QFT-GIT positivity rates at
BCHD. The model incorporates US and foreign-born to account for different LTBI prevalence in these two populations. In the Standard Algorithm,
all individuals are offered LTBI treatment. In the QFT-GIT Algorithm, all individuals receive QFT-GIT and only those that are positive are provided
LTBI treatment. LTBI treatment completion rates are based on current BCHD data. Individuals with incomplete treatment were considered to have
only partial treatment efficacy. It is assumed that individuals without LTBI were unable to progress to active TB disease.
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Table 1 Key Parameters for Cost-Effectiveness Analysis
Variable Base-Case Low High Source
Epidemiologic/Diagnostic/Treatment Parameters
Lifetime LTBI progression to active TB 5% 1% 15% [12,13]
Percent of LTBI referrals that are foreign-born 64% 30% 100% [4]
Percent of QFT-GIT positivity in BCHD 57% FB; 36% US – – BCHD, [4]
Prevalence of LTBI in TST-positive referrals 70% FB; 43% US 0% 100% Calculated;[4]
Sensitivity of QFT-GIT 81% 36% 100% [8,9,14]
Specificity of QFT-GIT 99% 90% 100% [8]
Percent of LTBI patients treated with 4Rif 62% 0% 100% BCHD
LTBI treatment completion for 9INH (4Rif) 52% (73%) 25% 100% BCHD, [15,16]
Drug-induced liver injury (percent severe) 1% (0.002%) 0% 6% BCHD, [13,15,17-20]
Efficacy of LTBI treatment medications 0.9 0.50 1 [3,17,21,22]
QFT-GIT Costs 2012 US$
QFT-GIT tubes $7.10/test $6.60 $12.42 BCHD
Phlebotomy supplies and clinic supplies $2.18 $0.55 $3.82 BCHD
QFT-GIT kit $23.92/test* $9.90* $71.75* BCHD
QFT-GIT lab consumables $3.50/test $.87 $6.12 BCHD
Total equipment costs for QFT-GIT testing†† $1.14/test $.29 $1.99 BCHD
Phlebotomist labor for QFT-GIT $1.60/test $1.60 $3.99 BCHD
Laboratory labor for QFT-GIT $2.28/test $1.48 $2.52 BCHD
Overhead for QFT-GIT testing $0.53/sample $0.25 $2.50 BCHD
TB Treatment Costs
Initial LTBI evaluation labor $35.04 $15.88 $68.29 BCHD
Labor LTBI treatment: 9INH $88.56 $36.40† $171† BCHD
Labor LTBI treatment: 4Rif $44.28 $18.20† $85.70† BCHD
Drug costs 9INH $26.82/course $9.27 $91.35 BCHD
Drug costs 4Rif $102.12/course $102.12 $482.60 BCHD
Chest x-ray $100 $50 $175 BCHD
Mild hepatitis $41.62 $0 $344 BCHD, [21]
Severe hepatitis $124.86 $41.62 $23,818 BCHD, [21]
Cost of active TB (includes drugs, staff, labs) $8,568 $2,142 $64,195 BCHD, [20,21,23]
Utilities
Well 1 [21]
9INH treatment 0.95 .9 .99 [20,21]
4Rif treatment 0.99 .9 .99 [20,21]
Mild hepatitis 0.85 1 mo 12 mo [20,21]
Severe hepatitis 0.40 0.1 0.4 [20,21]
Active TB ** 0.85 0.5 0.9 [21]
Fatal TB ** 0.5 0.1 0.5 [21]
Death 0 [21]
Note. LTBI = latent tuberculosis infection; TB = tuberculosis; QFT-GIT = QuantiFERON-TB Gold In-Tube; TST = tuberculin skin test; 4Rif = 4-month regimen of
Rifampin; 9INH = 9-month regimen of Isoniazid; BCHD = Baltimore City Health Department records.
* The base-case assumes a batch size of 24 patient samples per run. Low and high estimates are based on batch sizes ranging from 8 to 58 patient samples per
run.
† Low and high estimates based on variable staff salary and time spent per appointment.
†† Includes costs for an Automated ELISA instrument, software, incubator, centrifuge, and other non-consumable laboratory equipment.
**Sensitivity analyses incorporated range of utility weights, along with low and high estimates for life-expectancy after TB disease, and low and high estimates of
TB related mortality.
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identifying LTBI [6,25,26]. Given parameter uncertain-
ties, a wide range of QFT-GIT test characteristics and
LTBI prevalence were explored in sensitivity-analysis.
At BCHD, individuals diagnosed with LTBI are treated
with a 9-month regimen of Isoniazid (9INH) or a
4-month regimen of Rifampin (4Rif ), as per CDC guide-
lines [3]. Treatment completion rates were incorporated
into the model. For the base-case, lifetime risk of pro-
gression to active TB disease among those with un-
treated LTBI was assumed to be 5% at an average of
5 years from time of referral [6,12,21,25,27]. LTBI treat-
ment regimens were assumed to have 90% treatment
efficacy if completed [3,22]; given variability in timing of
drug discontinuation and efficacy of partial treatment,
incomplete treatment was assumed to offer on average
25% of complete treatment protection [17,21,22]. Indivi-
duals experiencing hepatotoxicity were assumed to
complete only partial treatment. Mean age at time of
referral to BCHD was 36 years (SD 16 years).
Outcome parameters
The primary outcomes were the expected costs per re-
ferral, Quality-Adjusted Life Years (QALYs) accrued per
referral, and expected active TB disease cases per referral
comparing the Intervention to Standard algorithms.
Cost-effectiveness was represented using Incremental
Cost-Effectiveness Ratios (ICERs), expressed as $US
Dollars/QALY-gained [28]; a probabilistic sensitivity ana-
lysis was additionally performed using monte-carlo
simulation methods to generate 95% confidence intervals
and explore varying willingness to pay thresholds.
QALYs accrued based on years of remaining life ex-
perienced with utility weights shown in Table 1 [29].
Mortality for individuals developing active TB disease
was assumed to be 5% in the base-case [21,30]. Future
QALYs were discounted at 3%.
Costs
Costs associated with LTBI evaluation and treatment
were collected at BCHD. QFT-GIT test costs were col-
lected from the time of specimen collection through
reporting of completed test results. QFT-GIT is cur-
rently performed at an off-site local BCHD laboratory at
a location separate from the BCHD TB clinic, with sam-
ples transported daily. An “ingredients” approach was
used, which involved multiplying input quantities used
by unit prices. Staff time, consumable supplies, and
equipment quantities utilized for performing the QFT-GIT
test were determined through direct observation of testing
procedures and time-motion studies. QFT-GIT tests
were assumed to be performed in batches of 24
based on current laboratory practice and batch size
was varied in sensitivity-analysis. Capitol item costs
were estimated from manufacturer quotations and/or
laboratory invoices and were annualized over their
useful lifespans as estimated by the laboratory ma-
nager. Overhead laboratory costs were determined,
including those for quality assurance, specimen
transport, supply delivery, and estimates for rent and
utilities attributable to QFT-GIT testing based on
building space and volume of testing. Costs of LTBI
treatment included drug costs based on invoices.
Labor costs were determined based on clerical and
clinician staff time spent during an average office
visit. One office visit was included for initial evalu-
ation and monthly office visits were included for
patients on LTBI treatment. Translation service costs
were added for non-English speaking patients. Costs
associated with drug toxicity were based on BCHD esti-
mates of additional diagnostic testing and clinic visits.
There is little recent published literature on the down-
stream costs associated with developing active TB disease
[21,23]. As such, base-case estimates for BCHD costs per
patient were based on current staff, drug, and diagnostic
expenditures for an average active TB case; uncomplicated
active TB cases were assumed to require only outpatient
treatment with no hospital days. Each individual was
assumed to receive standard drug treatment, directly
observed, with routine monitoring for treatment response
and toxicity [31]. Potential inpatient hospitalization costs
associated with active TB disease were incorporated into
the sensitivity-analysis. All key costs were explored in
sensitivity-analysis; when published estimates of cost ranges
were unavailable, potential price variations of 75% were
explored. Costs are presented in $US 2012 and future costs
were discounted at 3%.
Results
QFT-GIT testing costs
In the base-case, the total cost of performing the QFT-GIT
test at BCHD was $43.51 per test; of total test costs,
QFT-GIT tubes accounted for 17% ($7.10 per test), the
QFT-GIT ELISA kit for 57% ($23.92 per test), and
labor 9% ($3.88 per test), with the remaining 17%
($7.34 per test) attributable to other supplies, equip-
ment, and overhead (Table 1). If batch size of
QFT-GIT tests per run were increased from the BCHD
average of 24 to 58 as per manufacturer maximum, net
QFT-GIT cost was $27.68 per test; net QFT-GIT cost
was $97.47 for a batch size of 8. In sensitivity-analyses,
net QFT-GIT cost per individual ranged from $22.17 to
$108.25 when component costs for consumables, over-
head, labor, and equipment were varied.
Cost of LTBI-care for TST-positive referrals
In the base-case, the Intervention cost an additional
$10.12 per referral compared to the Standard ($370.04
versus $359.93) when all health-system costs were
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considered (Table 2). When examining only LTBI-care
costs (i.e. excluding downstream active TB disease costs),
the Intervention saves $22.89 per referral compared to
the Standard ($252.50 versus $275.39, Table 2), with
total LTBI-related program savings of $11,445 per year
(assuming 500 referrals per year, Table 3). These LTBI
savings were offset by potential additional costs ($33.00
per referral, Tables 2 and 3) related to more predicted
active TB cases in the Intervention compared to Stand-
ard when all health-system costs are considered. Assum-
ing QFT-GIT sensitivity was 100% for identifying LTBI
patients, the Intervention would be less costly compared
to the Standard ($353.29 versus $359.93).
There were several scenarios under which the Inter-
vention was less costly compared with the Standard, in-
cluding when QFT-GIT test costs are below $33.40,
4RIF drug costs increase above $142 per treatment
course, or QFT-GIT sensitivity is above 93%. However,
incremental costs for the Intervention compared to the
Standard were greater with rising active TB disease-
associated costs, increased progression rates to active TB
disease, or higher QFT-GIT testing costs.
Impact on QALYs and progression to active TB
In the base-case, the Intervention was more effective
than the Standard (0.01 QALYs-gained per referral for
Intervention). This benefit was seen despite a slightly
higher expected rate of progression to active TB disease
with the Intervention in the base-case (incremental in-
crease of 3.8 active TB disease cases per 1000 referrals).
In one-way sensitivity-analysis, the incremental benefit
associated with the Intervention was most sensitive to
the treatment regimen used for LTBI and increased to
0.022 QALYs gained per referral if 9INH is preferentially
used over 4Rif. The only condition in which the Stand-
ard was considered more effective was if lifetime pro-
gression rates to active TB disease among those with
LTBI increase above 14%.
Cost-effectiveness
For the base-case scenario, implementation of QFT-GIT
for adjunctive testing was associated with an ICER of
$1,202 per QALY-gained compared to the Standard, and
would be considered highly cost-effective compared to a
willingness-to-pay (WTP) threshold of $50,000/QALY-
gained for the US [32]. Without 3% annual discounting,
the ICER rises to $3,331 per QALY-gained.
One-way sensitivity-analyses were performed on all
key model parameters, and Figure 2 shows the variables
found to have the most effect on the base-case ICER.
There were no conditions in which the ICER for the
Intervention rose above the WTP threshold, and the
Intervention was therefore considered the preferred algo-
rithm. There were several conditions in which the Inter-
vention would be considered cost-saving. In particular,
the Intervention dominates (i.e. cheaper and more effect-
ive) the Standard algorithm when QFT-GIT sensitivity is
above 92%, 4RIF drug costs increase above $142 per
treatment course, or if less than 2.5% of individuals with
LTBI progressed to active TB disease over their lifetime.
We additionally explored the impact of assumptions
regarding utility weights of LTBI therapy and active TB
disease. If QALY losses attributable to LTBI therapy with
INH are reduced (i.e. utility weight increased to 0.99),
Table 2 Costs and Effects of Intervention Compared to Standard Algorithm in the Base-Case
Variable Standard Strategy QFT-GIT Strategy Incremental
Costs
Costs per Individual
QFT-GIT testing costs $0.00 $43.51 $43.51
LTBI treatment and monitoring $275.39 $208.99 -$66.40
Total LTBI-care costs $275.39 $252.50 -$22.89
Active TB costs per individual* $84.54 $117.54 $33.00
Net costs per individual $359.93 $370.04 $10.12
Effects
QALYs** 25.21 per referral 25.22 per referral 0.01 QALYs gained per referral
Active TB 9.9 per 1000 referrals 13.7 per 1000 referrals 3.8 per 1000 referrals
Cost-Effectiveness
Base-Case – – $1,202 per QALY-gained†
Note. QFT-GIT = QuantiFERON-TB Gold In-Tube; LTBI = latent tuberculosis infection; TB = tuberculosis; BCHD = Baltimore City Health Department; QALYs = Quality-
Adjusted Life Years.
*Active TB costs attributable to individuals referred to the BCHD TB Control Program who go on to develop active TB disease later in life; future costs were
discounted at 3%.
**Future QALY’s were discounted at 3%.
†ICER calculated as incremental costs divided by incremental effects ($10.12/0.01QALY’s gained).
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the ICER comparing the Intervention to Standard
increases to $14452 per QALY-gained. The ICER ranged
from $1180-$1400 per QALY gained when the utility
weight associated with active TB disease was varied be-
tween 0.9 and 0.5; if mortality among those developing
TB disease increases above 14%, the Standard algorithm
was found to dominate the Intervention. Drug toxicity
was found to have little impact on the ICER ($999 to
$1246 per QALY-gained, when percentage experiencing
LTBI treatment related liver injury was varied from 0-
6%, respectively).
Two-way sensitivity-analyses further examined the im-
pact of LTBI prevalence among TST-positive referrals
and QFT-GIT sensitivity (Figure 3). At current WTP
threshold, the QFT-GIT testing strategy remained the
preferred option at most permutations of LTBI preva-
lence and QFT-GIT sensitivity, and became cost-saving
regardless of QFT-GIT sensitivity if true LTBI prevalence
Table 3 Health Department Costs and Budgetary Impact Per Year (500 Referrals)
BCHD TB Control Program Costs Standard Strategy QFT-GIT Strategy Incremental
Referrals per year 500 500
Total QFT-GIT testing costs per year $0.00 $21755.00 $21755.00
Total LTBI treatment and monitoring costs per year $137695.00 $104495.00 -$33200.00
Total LTBI-care costs per year $137695.00 $126250.00 -$11445.00
Total active TB costs per year* $42270.00 $58770.00 $16500.00
Net costs $179965.00 $185020.00 $5060.00
*Active TB costs attributable to individuals referred to the BCHD TB Control Program who go on to develop active TB disease later in life using a 5 year analytic
time horizon; future costs were discounted at 3%. Without discounting, the costs would be $49,005 and $68,135 for the Standard and QFT-GIT strategies,
respectively.
Figure 2 One-Way Sensitivity-Analysis of Key Model Parameters. Line represents incremental cost-effectiveness ratio (ICER) when using base-
case estimates of all parameters. Not all parameters tested in sensitivity-analysis are shown. Top 12 factors affecting ICER are shown. EV-expected
value of the ICER under base-case parameters.
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among TST-positive referrals fell below approximately
40%. For scenarios of true LTBI prevalence greater than
95% among TST-positive referrals, treating all indivi-
duals becomes the preferred strategy regardless of
QFT-GIT sensitivity.
Monte-Carlo simulation methods were used to con-
duct a probabilistic sensitivity-analysis (PSA) and results
are shown in Figure 4. The mean ICER was $2,408 per
QALY-gained [95%CI; -$12,480 to $21,496]. The mean
incremental cost for the Intervention was $30.53 per re-
ferral [95%CI; -$54.68 to $143.79]; the mean incremental
effect was 0.018 QALYs-gained [95%CI; -0.02 to 0.05].
The Intervention was considered cost-effective 89.1% of
the time (WTP $50,000) and the Intervention dominated
the Standard 25% of the time (i.e. WTP $0).
Discussion
In the US, LTBI screening and treatment occurs in the
public and private health sectors with costs spread
amongst different entities. In Baltimore City, LTBI
screening is largely conducted by community sources
using TST, while treatment is typically provided by
BCHD [4]. LTBI treatment of all TST-positive indivi-
duals, however, is costly and labor intensive and may
lead to overtreatment in this low prevalence setting
[4,5,11]. These results suggest that BCHD implementa-
tion of adjunctive QFT-GIT testing for individuals re-
ferred by community sources with a positive TST is
highly cost-effective and potentially cost-saving.
Previously, there has been limited cost data to guide
QFT-GIT implementation in US public health clinics
A) Two-Way Sensitivity analysis (WTP $0) B) Two-Way Sensitivity analysis (WTP $50,000)
Figure 3 Two-Way Sensitivity-Analysis of QFT-GIT Sensitivity and LTBI Prevalence. Blue represents parameters at which Standard Algorithm
is preferred option and red represents parameters at which QFT-GIT Algorithm is the preferred option given willingness to pay threshold (WTP):
A) Two-way sensitivity analysis of LTBI prevalence versus QFT-GIT sensitivity at WTP threshold of $0 per QALY-gained; B) Two-way sensitivity
analysis of LTBI prevalence versus QFT-GIT sensitivity at WTP threshold of $50,000 per QALY-gained.
A) Cost-effectiveness Acceptability Curve B) Incremental costs and effects of QFT-GIT vsStandard Algorithm
Figure 4 Results from a Probabalistic Sensitivity-Analysis using Monte Carlo Simulation Methods. A) Cost-effectiveness acceptability curve
showing probability that the intervention will be cost-effective compared to treating all TST-positive referrals at varying willingness-to-pay
thresholds. B) Incremental cost-effectiveness of QFT-GIT vs. Standard Algorithm during iterations of Monte Carlo Simulation. Ellipse represents
95% confidence points. Diagonal dashed line represents ICERs at a WTP threshold of $50,000. Points to the right of this dashed line are
considered cost-effective. Dotted horizontal line shows incremental cost of $0.
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[21,33,34]. As currently implemented at BCHD, the
QFT-GIT test costs $43.51 per individual when all test-
related factors were considered and were strongly influ-
enced by testing volume.
The optimal algorithm for LTBI care is likely to be
impacted by TB program structure, resources, outcome
preferences, and regional epidemiology. This analysis
provides several details to aid programmatic decision-
making with respect to QFT-GIT use. For example, at
BCHD, staff available for LTBI care is limited. Providing
LTBI care and treatment for all TST-positive referrals (at
a cost of $275 per individual) resulted in annual LTBI
associated program costs exceeding $137,000. BCHD
implementation of adjunctive QFT-GIT testing in 2010
substantially reduced the number of individuals diag-
nosed with and treated for LTBI and is expected to save
the program nearly $23 per referral in LTBI-related costs
[4]. Such savings may allow public health departments
to reallocate LTBI resources to other activities, including
care of active TB patients and their contacts.
On the other hand, this study also suggests that ad-
junctive QFT-GIT testing for TST-positive individuals
may result in a small proportion of individuals with true
M. tuberculosis infection remaining untreated, resulting
in nearly four additional cases of active TB disease per
1,000 referrals. When active TB disease-associated costs
were considered, QFT-GIT implementation at BCHD
resulted in a net increase in health-system costs of
$10.12 per referral compared to treating all TST-positive
individuals. Importantly, however, the QFT-GIT testing
strategy was associated with overall increases in QALYs
despite the small increase in active TB cases, a conse-
quence of substantially fewer individuals being pre-
scribed LTBI treatment and less related adverse events.
This analysis highlights the need for programs to care-
fully weigh the potential health benefits of reduced LTBI
treatment with the potential risk of slight increases in
active TB cases. Moreover, sensitivity-analysis demon-
strated that QFT-GIT implementation became the do-
minant strategy (both cost-saving and more effective) if
true QFT-GIT sensitivity for detecting LTBI is above
92% or if the proportion of individuals with LTBI pro-
gressing to active TB disease is less than 3.5%.
This study has several limitations. Conducting eco-
nomic evaluations of LTBI diagnostic algorithms is com-
plicated by uncertainty about true LTBI prevalence
among those with discordant TST and QFT-GIT results.
Determining whether an individual has true LTBI is
challenging given the lack of a reference standard test,
making sensitivity and specificity estimates for diagnostic
tests less certain. Moreover, the target population con-
sisted of individuals referred from heterogeneous com-
munity sources in whom there is likely a broad range of
true M. tuberculosis infection risk and of progression to
active TB disease. Nonetheless, extensive sensitivity-
analyses explored the impact of variability in all key
parameters; QFT-GIT implementation was cost-effective
nearly 90% of the time at current WTP thresholds. This
analysis also assumed complete reliance on QFT-GIT
test results to determine LTBI status. Per current guide-
lines, clinicians may incorporate information about
quantitative TST and QFT-GIT results, immunosuppres-
sion, and other clinical information to determine LTBI
status [4,9]. Finally, this study was limited to assessing
cost-effectiveness of QFT-GIT testing for a population
of TST-positive individuals in a low prevalence setting
and our results may not apply to all other risk groups or
settings.
Conclusions
Overall, this study offers detailed cost information for
both QFT-GIT test implementation and LTBI treatment
in a representative public health TB program in the US.
Given reductions in public health funding, optimizing
resources for TB control is critical and this analysis
suggests that incorporation of QFT-GIT testing for
TST-positive individuals is likely highly cost-effective in
low-prevalence settings. Further studies are needed to
assess rates of progression from LTBI to active TB dis-
ease in individuals with discordant TST and QFT-GIT
test results. Recent literature suggests that QFT-GIT
may have a high negative predictive value for identifying
those at risk for progression to active TB disease
[6,25,26]; in this scenario, a strategy of adjunctive
QFT-GIT testing is likely to be not only cost-effective but
cost-saving.
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